Receptor tyrosine kinase-like orphan receptor 1 (ROR-1): An emerging target for diagnosis and therapy of chronic lymphocytic leukemia

Biomedicine and Pharmacotherapy

Volumn 88, Issue , 2017, Pages 814-822

  Aghebati Maleki, Leili ^a,b   Shabani, Mahdi ^c   Baradaran, Behzad ^a,b   Motallebnezhad, Morteza ^a,b   Majidi, Jafar ^a,b   Yousefi, Mehdi ^a,b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CLL; Diagnosis; ROR 1; Therapy; Tyrosine kinase

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 1; UNCLASSIFIED DRUG; ROR1 PROTEIN, HUMAN; TUMOR MARKER;

CELL THERAPY; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; ANIMAL; BIOSYNTHESIS; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM;

ANIMALS; BIOMARKERS, TUMOR; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS;

EID: 85012307829     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2017.01.070     Document Type: Review

References (95)

1. [1] Ko, E.C., Wang, X., Ferrone, S., Immunotherapy of malignant diseases Challenges and strategies. Int. Arch. Allergy Immunol. 132:4 (2003), 294–309.
2. [2] Weinstein, I.B., Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis 21:5 (2000), 857–864.
3. [3] Tsai, C.J., Nussinov, R., The molecular basis of targeting protein kinases in cancer therapeutics. Semin. Cancer Biol. 23:August (4) (2013), 235–242.
4. [4] Shah, D.R., Shah, R.R., Morganroth, J., Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Saf. 36:6 (2013), 413–426.
5. [5] Novellino, L.C.C., Parmiani, G., A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother. 54:3 (2005), 187–207.
6. [6] Krause, D.S., Van Etten, R.A., Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353:2 (2005), 172–187.
7. [7] Hubbard, S.R., Till, J.H., Protein tyrosine kinase structure and function. Annu. Rev. Biochem. 69 (2000), 373–398.
8. [8] Forrester, W.C., The Ror receptor tyrosine kinase family. Cell. Mol. Life Sci. 59:1 (2002), 83–96.
9. [9] Nishikawa, R.J.X., Harmon, R.C., et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. U. S. A. 91:16 (1994), 7727–7731.
10. [10] Bertram, J.S., The molecular biology of cancer. Mol. Aspects Med. 21:December (6) (2000), 167–223.
11. [11] Shabani, M., Asgarian-Omran, H., Jeddi-Tehrani, M., Vossough, P., Faranoush, M., Sharifian, R.A., Toughe, G.R., Kordmahin, M., Khoshnoodi, J., Roohi, A., Tavoosi, N., Mellstedt, H., Rabbani, H., Shokri, F., Overexpression of orphan receptor tyrosine kinase Ror1 as a putative tumor-associated antigen in Iranian patients with acute lymphoblastic leukemia. Tumour Biol. 28:6 (2007), 318–326, 10.1159/000121405.
12. [12] DeSantis, C.E., Lin, C.C., Mariotto, A.B., Siegel, R.L., Stein, K.D., Kramer, J.L., Alteri, R., Robbins, A.S., Jemal, A., Cancer treatment and survivorship statistics, 2014. CA Cancer J. Clin. 64:July–August (4) (2014), 252–271.
13. [13] Masiakowski, P.C.R., A novel family of cell surface receptors with tyrosine kinase-like domain. J. Biol. Chem. 267 (1992), 26181–26190.
14. [14] Forrester, W.C., Dell, M., Perens, E., Garriga, G., A C. elegans Ror receptor tyrosine kinase regulates cell motility and asymmetric cell division. Nature 400 (1999), 881–885.
15. [15] Kaucká, M.K.P., Plevová, K., Pavlová, Š., Procházková, J., Janovská, P., Valnohová, J., Kozubík, A., Pospíšilová, Š., Bryja, V., Post-translational modifications regulate signalling by Ror1. Acta Physiol. 203 (2011), 351–362.
16. [16] Tseng, H.-C., Lyu, P.-C., Lin, W-c., Nuclear localization of orphan receptor protein kinase (Ror1) is mediated through the juxtamembrane domain. BMC Cell Biol., 11(1), 2010, 48.
17. [17] Tseng, H.-C., Kao, H.-W., Ho, M.-R., Chen, Y.-R., Lin, T.-W., Lyu, P.-C., et al. Cytoskeleton network and cellular migration modulated by nuclear-localized receptor tyrosine kinase ROR1. Anticancer Res. 31:12 (2011), 4239–4249.
18. [18] Green, J.L., Kuntz, S.G., Sternberg, P.W., Ror receptor tyrosine kinases: orphans no more. Trends Cell Biol. 18:11 (2008), 536–544.
19. [19] Gentile, A., Lazzari, L., Benvenuti, S., Trusolino, L., Comoglio, P.M., Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer Res. 71:8 (2011), 3132–3141.
20. [20] Borcherding, N., Kusner, D., Liu, G.-H., Zhang, W., ROR1, an embryonic protein with an emerging role in cancer biology. Protein Cell 5:7 (2014), 496–502.
21. [21] Oishi, I., Takeuchi, S., Hashimoto, R., Nagabukuro, A., Ueda, T., Liu, Z.J., et al. Spatio‐temporally regulated expression of receptor tyrosine kinases, mRor1, mRor2, during mouse development: implications in development and function of the nervous system. Genes Cells 4:1 (1999), 41–56.
22. [22] Masiakowski, P., Carroll, R.D., A novel family of cell surface receptors with tyrosine kinase-like domain. J. Biol. Chem. 267:36 (1992), 26181–26190.
23. [23] Bicocca, V.T., Chang, B.H., Masouleh, B.K., Muschen, M., Loriaux, M.M., Druker, B.J., Tyner, J.W., Crosstalk between ROR1 and the pre-B Cell receptor promotes survival of t (1;19) acute lymphoblastic leukemia. Cancer Cell 22 (2012), 656–667.
24. [24] Yamaguchi, T., Yanagisawa, K., Sugiyama, R., Hosono, Y., Shimada, Y., Arima, C., et al. NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell 21:3 (2012), 348–361.
25. [25] Bainbridge, T.W., DeAlmeida, V.I., Izrael-Tomasevic, A., Chalouni, C., Pan, B., Goldsmith, J., et al. Evolutionary divergence in the catalytic activity of the CAM-1 ROR1 and ROR2 kinase domains. PLoS One, 9(7), 2014, e102695.
26. [26] Matsuda, T., Nomi, M., Ikeya, M., Kani, S., Oishi, I., Terashima, T., et al. Expression of the receptor tyrosine kinase genes, Ror1 and Ror2, during mouse development. Mech. Dev. 105:1 (2001), 153–156.
27. [27] Forrester, W.C., Dell, M., Perens, E., Garriga, G.A.C., elegans Ror receptor tyrosine kinase regulates cell motility and asymmetric cell division. Nature 400:6747 (1999), 881–885.
28. [28] Kim, C., Forrester, W.C., Functional analysis of the domains of the C elegans Ror receptor tyrosine kinase CAM-1. Dev. Biol. 264:2 (2003), 376–390.
29. [29] Roszmusz, E., Patthy, A., Trexler, M., Patthy, L., Localization of disulfide bonds in the frizzled module of Ror1 receptor tyrosine kinase. J. Biol. Chem. 276:21 (2001), 18485–18490.
30. [30] Paganoni, S., Ferreira, A., Neurite extension in central neurons: a novel role for the receptor tyrosine kinases Ror1 and Ror2. J. Cell Sci. 118:Jaunuary Pt 2 (2005), 433–446.
31. [31] Yamaguchi, T., Lu, C., Ida, L., Yanagisawa, K., Usukura, J., Cheng, J., Hotta, N., Shimada, Y., Isomura, H., Suzuki, M., Fujimoto, T., Takahashi, T., ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1. ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1. Nat. Commun., 7(January), 2016, 10060.
32. [32] Yoda, A., Oishi, I., Minami, Y., Expression and function of the Ror-family receptor tyrosine kinases during development: lessons from genetic analyses of nematodes, mice, and humans. J. Recept. Signal Transduct. 23:1 (2003), 1–15.
33. [33] Nomi, M., Oishi, I., Kani, S., Suzuki, H., Matsuda, T., Yoda, A., et al. Loss of mRor1 enhances the heart and skeletal abnormalities in mRor2-deficient mice: redundant and pleiotropic functions of mRor1 and mRor2 receptor tyrosine kinases. Mol. Cell. Biol. 21:24 (2001), 8329–8335.
34. [34] DeChiara, T.M., Kimble, R.B., Poueymirou, W.T., Rojas, J., Masiakowski, P., Valenzuela, D.M., et al. Ror2, encoding a receptor-like tyrosine kinase, is required for cartilage and growth plate development. Nat. Genet. 24:3 (2000), 271–274.
35. [35] Takeuchi, S., Takeda, K., Oishi, I., Nomi, M., Ikeya, M., Itoh, K., et al. Mouse Ror2 receptor tyrosine kinase is required for the heart development and limb formation. Genes Cells 5:1 (2000), 71–78.
36. [36] Al-Shawi, R.A.S., Underwood, C., Simons JP Expression of the Ror1 and Ror2 receptor tyrosine kinase genes during mouse development. Dev. Genes Evol. 211 (2001), 161–171.
37. [37] Matsuda, T.N.M., Ikeya, M., Kani, S., Oishi, I., Terashima, T., Takada, S., Minami, Y., Expression of the receptor tyrosine kinase genes, Ror1 and Ror2, during mouse development. Mech. Dev. 105 (2001), 153–156.
38. [38] Baskar, S., Kwong, K.Y., Hofer, T., Levy, J.M., Kennedy, M.G., Lee, E., Staudt, L.M., Wilson, W.H., Wiestner, A., Rader, C., Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin. Cancer Res. 14 (2008), 396–404.
39. [39] Hudecek, M.S.T., Baskar, S., Lupo-Stanghellini, M.T., Nishida, T., Yamamoto, T.N., Bleakley, M., Turtle, C.J., Chang, W.-C., Greisman, H.A., et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 116 (2010), 4532–4541.
40. [40] Daneshmanesh, A.H., Mikaelsson, E., Jeddi-Tehrani, M., Bayat, A.A., Ghods, R., Ostadkarampour, M., Akhondi, M., Lagercrantz, S., Larsson, C., Osterborg, A., Shokri, F., Mellstedt, H., Rabbani, H., Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int. J. Cancer 123 (2008), 1190–1195.
41. [41] Barna, G.M.R., Timár, B., Tömböl, J., Csende, Z., Sebestyén, A., Bödör, C., Csernus, B., Reiniger, L., Peták, I., et al. ROR1 expression is not a unique marker of CLL. Hematol. Oncol. 29 (2011), 17–21.
42. [42] Zhang, S.C.L., Cui, B., Chuang, H.-Y., Yu, J., Wang-Rodriguez, J., Tang, L., Chen, G., Basak, G.W., Kipps, T.J., ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS One, 7, 2012, e31127.
43. [43] MacKeigan, J.P., Murphy, L.O., Blenis, J., Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat. Cell Biol. 7:6 (2005), 591–600.
44. [44] Choudhury, A., Derkow, K., Daneshmanesh, A.H., Mikaelsson, E., Kiaii, S., Kokhaei, P., et al. Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells. Br. J. Haematol. 151:4 (2010), 327–335.
45. [45] Hojjat-Farsangi, M., Moshfegh, A., Daneshmanesh, A.H., Khan, A.S., Mikaelsson, E., Osterborg, A., Mellstedt, H., The receptor tyrosine kinase ROR1—an oncofetal antigen for targeted cancer therapy. Semin. Cancer Biol. 29 (2014), 21–31.
46. [46] Daneshmanesh, A.H., Porwit, A., Hojjat-Farsangi, M., Jeddi-Tehrani, M., Tamm, K.P., Grandér, D., et al. Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies. Leuk. Lymphoma 54:4 (2013), 843–850.
47. [47] Shabani, M., Asgarian-Omran, H., Hojjat-Farsangi, M., Vossough, P., Sharifian, R.A., Toughe, G.R., et al. Comparative expression profile of orphan receptor tyrosine kinase ROR1 in Iranian patients with lymphoid and myeloid leukemias. Avicenna J. Med. Biotechnol. 3:3 (2011), 119–125.
48. [48] Zhang, S.C.L., Wang-Rodriguez, J., Zhang, L., Cui, B., Frankel, W., Wu, R., Kipps TJ The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am. J. Pathol. 181 (2012), 1903–1910.
49. [49] Daneshmanesh, A.H., Hojjat-Farsangi, M., Moshfegh, A., Mikaelsson, E., Khan, A.S., Österborg, A., et al. Anti-ROR1 monoclonal antibodies induce apoptosis in pancreatic cancer cells via the PI3-kinase/AKT/mTOR pathway. Cancer Res., 74(19 Suppl), 2014, 4770.
50. [50] Widhopf, G.F., Prussak, C.E., Wu, C.C., Sadarangani, A., Zhang, S., Lao, F., et al. Cirmtuzumab vedotin (UC-961ADC3), an anti-ROR1-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for ROR1-positive leukemia and solid tumors. Blood, 122(21), 2013, 1637-.
51. [51] Frank, D.A., Mahajan, S., Ritz, J., B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J. Clin. Invest., 100(12), 1997, 3140.
52. [52] Li, P., Harris, D., Liu, Z., Liu, J., Keating, M., Estrov, Z., Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells. PLoS One, 5(7), 2010, e11859.
53. [53] Hojjat-Farsangi, M., Khan, A.S., Daneshmanesh, A.H., Moshfegh, A., Sandin, Å., Mansouri, L., et al. The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells. PLoS One, 8(10), 2013, e78339.
54. [54] Liu, Y., Ross, J.F., Bodine, P.V., Billiard, J., Homodimerization of Ror2 tyrosine kinase receptor induces 14-3-3β phosphorylation and promotes osteoblast differentiation and bone formation. Mol. Endocrinol. 21:12 (2007), 3050–3061.
55. [55] Liu, Y., Rubin, B., Bodine, P.V., Billiard, J., Wnt5a induces homodimerization and activation of Ror2 receptor tyrosine kinase. J. Cell. Biochem. 105:2 (2008), 497–502.
56. [56] Sammar, M., Stricker, S., Schwabe, G.C., Sieber, C., Hartung, A., Hanke, M., et al. Modulation of GDF5/BRI-b signalling through interaction with the tyrosine kinase receptor Ror2. Genes Cells 9:12 (2004), 1227–1238.
57. [57] Marth, J.D., Grewal, P.K., Mammalian glycosylation in immunity. Nat. Rev. Immunol. 8:11 (2008), 874–887.
58. [58] Widhopf, G.F., Cui, B., Ghia, E.M., Chen, L., Messer, K., Shen, Z., Briggs, S.P., Croce, C.M., Kipps, T.J., ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 111:January (2) (2014), 793–798.
59. [59] Craig, Fiona E., Foon, Kenneth A., Flow cytometric immunophenotyping for hematologic neoplasms. Blood 111 (2008), 3941–3967.
60. [60] Byrd, John C., Introduction to a series of reviews on chronic lymphocytic leukemia. Blood, 126, 2015, 427.
61. [61] Fabbri, G., Dalla-Favera, R., The molecular pathogenesis of chronic lymphocytic leukaemia. Nat. Rev. Cancer 16 (2016), 145–162.
62. [62] Uhrmacher, S., Schmidt, C., Erdfelder, F., Poll-Wolbeck, S.J., Gehrke, I., Hallek, M., et al. Use of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a diagnostic tool in chronic lymphocytic leukemia (CLL). Leuk. Res. 35:10 (2011), 1360–1366.
63. [63] Daneshmanesh, A., Hojjat-Farsangi, M., Khan, A., Jeddi-Tehrani, M., Akhondi, M., Bayat, A., et al. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells. Leukemia 26:6 (2012), 1348–1355.
64. [64] Rawstron, A., Villamor, N., Ritgen, M., Böttcher, S., Ghia, P., Zehnder, J., et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 21:5 (2007), 956–964.
65. [65] Elter, T., Hallek, M., Engert, A., Fludarabine in chronic lymphocytic leukaemia. Expert Opin. Pharmacother. 7:12 (2006), 1641–1651.
66. [66] Baskar, S., Wiestner, A., Wilson, W.H., Pastan, I., Rader, C., Targeting malignant B cells with an immunotoxin against ROR1. MAbs 4:May–June (3) (2012), 349–361.
67. [67] Cui, B., Widhopf, G.F., Chen, L., Rassenti, L., Wang, Z., Ma, S., et al. Preclinical development of ROR1 peptide based vaccine with activity against chronic lymphocytic leukemia in ROR1 transgenic mice. Blood, 122(21), 2013, 4174.
68. [68] Milani, A., Sangiolo, D., Montemurro, F., Aglietta, M., Valabrega, G., Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. Ann. Oncol. 24:July (7) (2013), 1740–1748.
69. [69] Baskar, S., Kwong, K.Y., Hofer, T., Levy, J.M., Kennedy, M.G., Lee, E., et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin. Cancer Res. 14:2 (2008), 396–404.
70. [70] Shabani, M., Naseri, J., Shokri, F., Receptor tyrosine kinase-like orphan receptor 1: a novel target for cancer immunotherapy. Expert Opin. Ther. Targets 19:July (7) (2015), 941–955 941-5519 (7).
71. [71] Maleki, L.A., Baradaran, B., Majidi, J., Mohammadian, M., Shahneh, F.Z., Future prospects of monoclonal antibodies as magic bullets in immunotherapy. Hum. Antibodies 22:1–2 (2013), 9–13.
72. [72] Aghebati-Maleki, L., Bakhshinejad, B., Baradaran, B., et al. Phage display as a promising approach for vaccine development. J. Biomed. Sci., 23, 2016, 66.
73. [73] Yang, J., Baskar, S., Kwong, K.Y., Kennedy, M.G., Wiestner, A., Rader, C., Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PLoS One, 6(6), 2011, e21018.
74. [74] Bae, J.H., Schlessinger, J., Asymmetric tyrosine kinase arrangements in activation or autophosphorylation of receptor tyrosine kinases. Mol. Cells 29:5 (2010), 443–448.
75. [75] Khoury, H., Dankort, D.L., Sadekova, S., Naujokas, M.A., Muller, W.J., Park, M., Distinct tyrosine autophosphorylation sites mediate induction of epithelial mesenchymal like transition by an activated ErbB-2/Neu receptor. Oncogene 20:7 (2001), 788–799.
76. [76] Noble, C., Mercer, K., Hussain, J., Carragher, L., Giblett, S., Hayward, R., et al. CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation. Mol. Cell 31:6 (2008), 862–872.
77. [77] Fukuda, T., Chen, L., Endo, T., Tang, L., Lu, D., Castro, J.E., Widhopf, G.F., Rassenti, L.Z., Cantwell, M.J., Prussak, C.E., Carson, D.A., Kipps, T.J., Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 3047–3052.
78. [78] Kalos, M., Levine, B.L., Porter, D.L., Katz, S., Grupp, S.A., Bagg, A., et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med., 3(95), 2011, 95ra73.
79. [79] Kochenderfer, J.N., Dudley, M.E., Feldman, S.A., Wilson, W.H., Spaner, D.E., Maric, I., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells. Blood 119:12 (2012), 2709–2720.
80. [80] Kochenderfer, J.N., Wilson, W.H., Janik, J.E., Dudley, M.E., Stetler-Stevenson, M., Feldman, S.A., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116:20 (2010), 4099–4102.
81. [81] Morgan, R.A., Dudley, M.E., Wunderlich, J.R., Hughes, M.S., Yang, J.C., Sherry, R.M., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:5796 (2006), 126–129.
82. [82] Porter, D.L., Levine, B.L., Kalos, M., Bagg, A., June, C.H., Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. New Engl. J. Med. 365:8 (2011), 725–733.
83. [83] Eshhar, Z., Waks, T., Gross, G., Schindler, D.G., Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. U. S. A. 90:2 (1993), 720–724.
84. [84] Kershaw, M.H., Teng, M.W., Smyth, M.J., Darcy, P.K., Supernatural T cells: genetic modification of T cells for cancer therapy. Nat. Rev. Immunol. 5:12 (2005), 928–940.
85. [85] Sadelain, M., Rivière, I., Brentjens, R., Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer 3:1 (2003), 35–45.
86. [86] Maude, Shannon L., Teachey, David T., Porter, David L., Grupp, Stephan A., CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 125 (2015), 4017–4023.
87. [87] Brentjens, R.J., Rivière, I., Park, J.H., Davila, M.L., Wang, X., Stefanski, J., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118:18 (2011), 4817–4828.
88. [88] Hudecek, M., Lupo-Stanghellini, M.-T., Kosasih, P.L., Sommermeyer, D., Jensen, M.C., Rader, C., et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin. Cancer Res. 19:12 (2013), 3153–3164.
89. [89] STI571, B.J.D., (Gleevec) as a paradigm for cancer therapy. Trends Mol. Med 8:4 Suppl (2002), S14–8.
90. [90] Davies, S.P., Reddy, H., Caivano, M., et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351:Pt 1 (2000), 95–105.
91. [91] Narayanan, R., Yepuru, M., Coss, C.C., et al. Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation. PLoS One, 8(12), 2013, e83380.
92. [92] Akinleye, A., Chen, Y., Mukhi, N., et al. Ibrutinib and novel BTK inhibitors in clinical development. J. Hematol. Oncol., 6, 2013, 59.
93. [93] Ponader, S., Chen, S.S., Buggy, J.J., et al. The Bruton tyrosine kinase inhibitor PCI- 32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119:5 (2012), 1182–1189.
94. [94] Daneshmanesh, A.H., Hojjat-Farsangi, M., Moshfegh, A., Khan, A.S., Mikaelsson, E., Österborg, A., Mellstedt, H., The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies. Br. J. Haematol. 169:3 (2015 May), 455–458.
95. [95] O'Connell, M.P., Marchbank, K., Webster, M.R., Valiga, A.A., Kaur, A., Vultur, A., et al. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov. 3:12 (2013), 1378–1393.